Table 1 Summary of patient characteristics.
From: Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency
ID | Diagnosis | Sex | Age (year) | Cell viability % | Allele |
|---|---|---|---|---|---|
HF370 | AATD | M | 68 | 80 | Z |
HF371 | Organ donor | M | 6 | 71 | M |
HF384 | AATD | M | 5 | 74 | Z |
HF395 | FAP | M | 31 | 82 | M |
HF399 | Organ donor | F | 40 | 84 | M |
HF403 | Organ donor | M | 68 | 78 | M |
HF414 | Organ donor | M | 27 | 82 | M |
HF423 | Colorectal metastasis | M | 73 | 79 | M |
HF424 | Colorectal metastasis | M | 68 | 67 | M |
HF425 | Cholangiocarcinoma | M | 73 | 71 | M |
HF426 | Unknown tumour | M | 71 | 80 | M |
HF433 | Colorectal metastasis | M | 73 | 66 | M |
HF435 | Colorectal metastasis | F | 81 | 66 | M |
HF440 | Organ donor | M | 63 | 80 | M |
HF455 | AATD | M | 0.8 | 78 | Z |
HF456 | Organ donor | M | 12 | 77 | M |
Diagnosis | n (total = 16) | Sex | |||
A1ATD | 3 (18,8%) | Female | 2 (12,5%) | ||
Cholangiocarcinoma | 1 (6,3%) | Male | 14 (87,5%) | ||
Colorectal metastasis | 4 (25%) | Cell isolation (mean) | |||
FAP | 1 (6,3%) | Age (years) | 47,5 (0.8–81) | ||
Organ donor | 6 (37,5%) | Tissue mass (g) | 258,4 (41–584) | ||
Unknown tumour | 1 (6,3%) | Cell viability (%) | 75,9 (66–84) |
